74882-32-9

Upstream product

• 41973-35-7 1.5-Di-(4-methoxyphenyl)-3-hydroxypentane 
• 2051-07-2 bis(p-methoxybenzylidene)acetone 
• 2051-07-2 1,5-bis-(4-methoxyphenyl)-1,4-pentadien-3-one 
• 67-56-1 methanol 
• 67-64-1 acetone 
• 105-13-5 4-Methoxybenzyl alcohol 
• 123-11-5 4-methoxy-benzaldehyde 
• 100-46-9 benzylamine 
• 637-69-4 4-Methoxystyrene 
• 143-33-9 sodium cyanide 

Downstream Products

• 13612-52-7 β-Hydroxy-β,β-di-<β'-(p-methoxy-phenyl)-aethyl>-propionsaeure-methylester 
• 13579-12-9 <1,5-Di-(p-methoxyphenyl)-3-pentyliden>-cyanacetamid 
• 93652-23-4 1,5-bis(4-hydroxyphenyl)-3-pentanone 
• 137794-33-3 2,6-bis(4'-methoxybenzyl)-4-nitrophenol 
• 199990-69-7 4-[5-Ethyl-4-(3-{4-(4-methoxy-phenyl)-2-[2-(4-methoxy-phenyl)-ethyl]-butylamino}-benzoyl)-1-methyl-1H-pyrrol-2-yl]-butyric acid ethyl ester 
• 137794-36-6 2,6-bis(4'-methoxybenzyl)-4-nitrophenylacetate 
• 137569-07-4 C₄₅H₅₀O₅ 
• 13612-53-8 β,β-Di-<β-(p-methoxy-phenyl)-aethyl>-acrylsaeure-methylester 
• 4877-10-5 1,5-bis(4-methoxyphenyl)pentane 
• 1374458-50-0 3,3-dihydroperoxy-1,5-bis(4'-methoxyphenyl)pentane 

Relevant academic research and scientific papers

Highly productive α-alkylation of ketones with alcohols mediated by an Ir-oxalamidato/solid base catalyst system

An Ir-oxalamidato complex in combination with a solid base (e.g., magnesium aluminometasilicate/Ca(OH)2) significantly improved the catalyst productivity in α-alkylation of methyl ketones with primary alcohols. Optimization through systematic variation of the oxalamidato ligand led to a practical turnover number (TON) of 10 000.40 000.

Antimicrobial Activity of Monoketone Curcuminoids Against Cariogenic Bacteria

We evaluated the antimicrobial activity of 25 monoketone curcuminoids (MKCs) against a representative panel of cariogenic bacteria in terms of their minimum inhibitory concentration (MIC) values. Curcumin A (10) displayed promising activity against Streptococcus mutans (MIC?=?50?μg/ml) and Streptococcus mitis (MIC?=?50?μg/ml) as well as moderate activity against S.?sanguinis (MIC?=?100?μg/ml), Lactobacillus casei (MIC?=?100?μg/ml), and Streptococcus salivarius (MIC?=?200?μg/ml). Results indicated higher activity of compound 10 than that of its bis-β-diketone analog. Additionally, compounds 3a (1,5-bis(4-methylphenyl)pentan-3-one) and 7b (1,5-bis(4-bromophenyl)pentan-3-ol) were moderately active against S.?mitis (MIC?=?100?μg/ml) and S.?salivarus (MIC?=?200?μg/ml).

NOVEL PYRAZINE AMIDE COMPOUNDS

The present invention relates to compounds of formula 1 or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, R6 and X- have one of the meanings as indicated in the specification, to their use as a medicament, to their use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways, to pharmaceutical composition comprising at least one of said compound or a pharmaceutically acceptable salt thereof, as well as to medicament combinations containing one or more of said compounds or a pharmaceutically acceptable salt thereof.

Tandem hydrogenation and condensation of fluorinated α,β-unsaturated ketones with primary amines, catalyzed by nickel

A simple homogeneous catalytic system based on nickel phosphine complexes has been developed for the transfer hydrogenation and condensation of α,β-unsaturated ketones to yield saturated ones and saturated imines using primary amines as hydrogen donors. Thus, a wide range of fluorinated 1,5-diaryl-1,4-pentadiene-3-ones were allowed to react with substituted benzylamines in the presence of [(dippe)Ni(μ-H)]2 (dippe = 1,2-bis-(diisopropylphosphino)-ethane) using ethanol as a solvent at 180 °C to give the corresponding saturated carbonyl compounds; here hydrogenation of the CC bond was preferred over the CO bond. Under the same reaction conditions but using an excess of benzylamine, a tandem process is then favoured, starting also with the reduction of the CC bond followed by a nucleophilic addition of the primary amine to yield valuable saturated imines with good to excellent yields (62%-91%).

Use of Saccharomyces cerevisiae yeasts in the chemoselective bioreduction of (1E,4E)-1,5-bis(4-methoxyphenyl)-1,4-pentadien-3-one in biphasic system

This work describes the chemoselective bioreduction of (1E,4E)-1,5-bis(4- methoxyphenyl)- 1,4-pentadien-3-one (1) mediated by baker's yeast (BY, Saccharomyces cerevisiae cells) in an aqueous/organic solvent biphasic system. The biotransformation of this c

Nickel-catalyzed alkylation and transfer hydrogenation of α,β-unsaturated enones with methanol

Complexes of the type [{(dippe)Ni} ( 2-Cα,Cβ- 1,4-dien-3-one)] (dippe = 1,2-bis(diisopropylphosphino)- ethane); n= 1, 2; enone = aromatic 1,4-pentadien-3-ones) were synthesized. The "[(dippe)Ni]" moiety derived from [(dippe)Ni(-H)]2 2-coordinated to the C,C double bonds of the corresponding α,β-unsaturated enone and was fully characterized using a variety of spectroscopic techniques, for instance, single-crystal X-ray diffraction, nuclear magnetic resonance (NMR), and mass spectrometry. The complexes were assessed in a catalytic transfer hydrogenation process using methanol (CH3OH) as a hydrogen donor. This alcohol turned out to be a very efficient reducing and alkylating agent of 1,4- pentadien-3-ones, under neat conditions. The current methodology allowed the selective reduction of C=C bonds in α,β- unsaturated enones to yield enones and saturated ketones by a homogeneous catalytic pathway, whereas by a heterogeneous pathway, the process leads to the formation of mono- and dimethylated ketones. In the latter case, the occurrence of nickel nanoparticles in the reaction media was found to participate in the catalytic alkylation of such dienones.

Pd-aminoclay nanocomposite as an efficient recyclable catalyst for hydrogenation and suzuki cross coupling reactions

A highly water dispersible Pd-aminoclay nanocomposite is found to be effective catalytic system for the hydrogenation of α,β-unsaturated carbonyl compounds and Suzuki coupling reactions in aqueous media. The catalytic hydrogenation of α,β-unsaturated carbonyl compounds proceeds at room temperature to afford the corresponding products in excellent yields with high chemoselectivity. The cross coupling of aryl bromides and iodides with aryl boronic acids proceeds efficiently under aqueous conditions at 90 °C to afford the corresponding biaryls in excellent yields with high selectivity. The Suzuki reaction proceeds smoothly even in the absence of external base due to the basic nature of the catalyst support. The catalyst could be easily recovered and recycled three times without a significant loss of activity in hydrogenation and Suzuki cross coupling reactions. Copyright

Synthesis and Antimalarial Activity of Dihydroperoxides and Tetraoxanes Conjugated with Bis(benzyl)acetone Derivatives

Dihydroperoxides and tetraoxanes derived from symmetrically substituted bis(arylmethyl)acetones were synthesized in modest to good yields using several methods. Three of these compounds exhibit an important in vitro antimalarial activity (1.0μm≤IC50≤5.0μm) against blood forms of the human malaria parasite Plasmodium falciparum.

Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives

The present invention relates to a method for the chemical separation of the enantiomers of 1,1′-spirobiindane-6,6′-diol derivatives comprising providing a racemic chiral 1,1′-spirobiindane-6,6′-diol derivative, reacting a nonracemic chiral component with

Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis

Symmetrical bis(quinolylmethoxyphenyl)alkylcarboxylic acids were investigated as inhibitors of leukotriene biosynthesis and 4,4-bis(4-(2-quinolylmethoxy)phenyl)pentanoic acid sodium salt (47·Na) met our design parameters for a drug candidate (ABT-080). This compound was readily synthesized in three steps from commercially available diphenolic acid. Against intact human neutrophils, 47·Na inhibited ionophore-stimulated LTB4 formation with an IC50 = 20 nM. In zymosan-stimulated mouse peritoneal macrophages producing both LTC4 and PGE2, 47·Na showed 9000-fold selectivity for inhibition of LTC4 (IC50 = 0.16 nM) over PGE2 (IC50 = 1500 nM). Preliminary pharmacokinetic evaluation in rat and cynomolgus monkey demonstrated good oral bioavailability and elimination half-lives of 9 and 5 h, respectively. Pharmacological evaluation of leukotriene inhibition with oral dosing was demonstrated in a rat pleural inflammation model (ED50 = 3 mg/kg) and a rat peritoneal passive anaphylaxis model (LTB4, ED50 = 2.5 mg/kg; LTE4, ED50 = 1.0 mg/kg). In a model of airway constriction induced by antigen challenge in actively sensitized guinea pigs, 47·Na dosed orally blocked bronchoconstriction with an ED50 = 0.4 mg/kg, the most potent activity we have observed for any leukotriene inhibitor in this model. The mode of inhibitory action of 47·Na occurs at the stage of 5-lipoxygenase biosynthesis as it blocks both leukotriene pathways leading to LTB4 and LTC4 but not PGH2 biosynthesis. However, 47·Na does not inhibit 5-lipoxygenase catalysis in a broken cell enzyme assay; therefore it is likely that 47·Na acts as a FLAP inhibitor.